Strategy for early diagnosis of lung involvement in systemic sclerodermia;Stratégie pour le diagnostic précoce de l'atteinte pulmonaire dans la sclérodermie systémique

Revue des Maladies Respiratoires

Volumn 17, Issue 6, 2000, Pages 1073-1080

  Diot, E ^a,b   Valat, C ^a,b   Boissinot, E ^a,b   Giraudeau, B ^a,b   Asquier, E ^a,b   Guilmot, J L ^a,b   Lemarie E ^a,b   Diot, P ^a,b  

^a CHU BRETONNEAU   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Anti topoisomerase I antibodies; Broncho alveolar lavage; Computed tomography; Procollagen; Pulmonary fibrosis; Pulmonary function tests; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; PATHOPHYSIOLOGY; PROGNOSIS; SYSTEMIC SCLEROSIS;

AFTERCARE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034495287     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pathologic observations in scleroderma
2. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
3. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis
4. Alveolar type II epithelial cells produce interleukine-6 in vitro and in vivo
5. Imaging of pulmonary disease in scleroderma with JOOIX scintigraphy
6. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
7. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparaison between the CREST syndrome and diffuse scleroderma
8. Scleroderma-clinical aspects
9. High resolution computed tomography as a predictior of lung histology in systemic sclerosis
10. Predictive value of serum procollagen for diagnosis of pulmonary involvement in patients with systemic sclerosis
11. Pulmonary involvement in progressive systemic sclerosis: Sequential evaluation with CT, pulmonary function tests and bronchoalveolar lavage
12. High resolution computed tomography in early scleroderma lung disease
13. Relationship between abnormalities on high resolution CT and pulmonary function in systemic sclerosis
14. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis
15. Serial pulmonary function tests in progressive scleroderma
16. Carbon monoxyde diffusing capacity as predictor of outcome in systemic sclerosis
17. Pulmonary involvement in scleroderma: The value of early changes by thin sections CT scan, bronchoalveolar lavage and 99m Tc DTPA clearance
18. Decrease in DLCO in systemic sclerosis correlates with acceleration of DTPA clearance
19. Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis
20. Physiopathologie de la sclérodermie
21. La microangiopathie sclérodermique: Cause ou consequence?
22. Vascular disease in progressive systemic sclerosis (scleroderma)
23. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis
24. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage
25. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsquent changes in lung function
26. High resolution computed tomography as a predictor of lung histology in systemic sclerosis
27. Sclérodermie et inflammation alvéolaire
28. Type III collagen amino-peptide levels in serum of patients with progressive systemic scleroderma
29. Serum and urinary amino terminal type III procollagen peptide in progressive scleroderma: Relationship to sclerodermal involvement serum hyaluronan and urinary collagen metabolites
30. Serum type III procollagen peptide concentrations in scleroderma and Raynaud's phenomenon: Relationship to disease activity and duration
31. Serum III procollagen, but not serum I procollagen, is predictive of lung involvement in systemic sclerosis
32. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph
33. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in tumor tissue and peritoneal cavity
34. Serological markers in progressive systémic sclerosis: Clinical correlations
35. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis
36. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis
37. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
38. Carbon monoxyde diffusing capacity as predictor of outcome in systemic sclerosis
39. The presence of Sjögren's syndrome is a major determinant of the pattern of interstitial lung disease in scleroderma and other connectivite tissue disease
40. Severe organ involvement in diffuse scleroderma occurs early in disease